FDA's Worst Case Scenario: Supreme Court Might Defer To It On Biosimilars
Executive Summary
During oral arguments in Sandoz v Amgen, justices suggest FDA issue rule-making on whether biosimilar sponsors can give early notification of launches and need to follow all the steps in the patent dance. The agency has explicitly said it wants to be left out of it.
You may also be interested in...
Amgen v. Sandoz: Next Biosimilar Bout Begins Over State Law Claims
In the ongoing Zarxio dispute, US appeals court takes up question left open by Supreme Court as to whether innovator company can seek remedy under state law if a biosimilar sponsor does not engage in the "patent dance" by providing its application and manufacturing information.
Amgen v. Sandoz: Next Biosimilar Bout Begins Over State Law Claims
In the ongoing Zarxio dispute, US appeals court takes up question left open by Supreme Court as to whether innovator company can seek remedy under state law if a biosimilar sponsor does not engage in the "patent dance" by providing its application and manufacturing information.
US Supreme Court Permits Earlier Biosimilar Launches; Penalty For Declining Patent Dance Uncertain
Court says biosimilar sponsors may provide 180-day notice of marketing prior to FDA approval; Federal Circuit to decide if innovators can seek an injunction under state law if sponsors do not provide application and manufacturing information; Justice Breyer offers FDA invitation to weigh in.